| # | Title | Journal | Year | Citations |
|---|
| 1 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update | Annals of the Rheumatic Diseases | 2017 | 3,366 |
| 2 | Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis | JAMA - Journal of the American Medical Association | 2014 | 566 |
| 3 | Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group | Annals of the Rheumatic Diseases | 2016 | 383 |
| 4 | Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis | Annals of the Rheumatic Diseases | 2014 | 270 |
| 5 | Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial | Lancet Rheumatology, The | 2019 | 250 |
| 6 | Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis | Annals of the Rheumatic Diseases | 2017 | 195 |
| 7 | International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials | Annals of the Rheumatic Diseases | 2017 | 194 |
| 8 | Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS) | Annals of the Rheumatic Diseases | 2017 | 107 |
| 9 | The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Double‐Blind, Placebo/Active‐Controlled, Dose‐Ranging Study | Arthritis and Rheumatology | 2015 | 86 |
| 10 | Review: Preclinical Rheumatoid Arthritis: Progress Toward Prevention | Arthritis and Rheumatology | 2016 | 81 |
| 11 | Regression of Peripheral Subclinical Enthesopathy in Therapy‐Naive Patients Treated With Ustekinumab for Moderate‐to‐Severe Chronic Plaque Psoriasis: A Fifty‐Two–Week, Prospective, Open‐Label Feasibility Study | Arthritis and Rheumatology | 2019 | 64 |
| 12 | Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study | Annals of the Rheumatic Diseases | 2016 | 63 |
| 13 | A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial | Annals of the Rheumatic Diseases | 2014 | 60 |
| 14 | Autoantibodies to Posttranslationally Modified Type II Collagen as Potential Biomarkers for Rheumatoid Arthritis | Arthritis and Rheumatism | 2013 | 59 |
| 15 | 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis | Rheumatology | 2017 | 59 |
| 16 | Safety of Paracetamol in Osteoarthritis: What Does the Literature Say? | Drugs and Aging | 2019 | 59 |
| 17 | Safety of Opioids in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis | Drugs and Aging | 2019 | 57 |
| 18 | Diagnostic test accuracy of ultrasound for synovitis in rheumatoid arthritis: systematic review and meta-analysis | Rheumatology | 2018 | 55 |
| 19 | Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study | Annals of the Rheumatic Diseases | 2018 | 50 |
| 20 | High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort | Annals of the Rheumatic Diseases | 2017 | 49 |
| 21 | Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients | Pharmacogenomics Journal | 2018 | 42 |
| 22 | Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy | Annals of the Rheumatic Diseases | 2014 | 39 |
| 23 | Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis | Arthritis Research and Therapy | 2019 | 38 |
| 24 | New GRAPPA and EULAR recommendations for the management of psoriatic arthritis | Rheumatology | 2017 | 36 |
| 25 | Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis? | Annals of the Rheumatic Diseases | 2015 | 33 |
| 26 | The involvement of the spine in psoriatic arthritis | Clinical and Experimental Rheumatology | 2015 | 33 |
| 27 | Discordance between the predictors of clinical and imaging remission in patients with early rheumatoid arthritis in clinical practice: implications for the use of ultrasound within a treatment-to-target strategy | Rheumatology | 2016 | 31 |
| 28 | Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission | Arthritis and Rheumatology | 2021 | 29 |
| 29 | Cross-phenotype analysis of Immunochip data identifies KDM4C as a relevant locus for the development of systemic vasculitis | Annals of the Rheumatic Diseases | 2018 | 27 |
| 30 | Quantitating Skin Fibrosis: Innovative Strategies and Their Clinical Implications | Current Rheumatology Reports | 2014 | 25 |
| 31 | Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial | RMD Open | 2017 | 24 |
| 32 | Extension Study of PF‐05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis | Arthritis Care and Research | 2018 | 22 |
| 33 | Patient-reported outcome measures in osteoarthritis: a systematic search and review of their use and psychometric properties | RMD Open | 2018 | 22 |
| 34 | Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study | Clinical Rheumatology | 2020 | 18 |
| 35 | Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review | Arthritis Research and Therapy | 2021 | 18 |
| 36 | Implementing the findings of the TICOPA trial in clinical practice: challenges in implementation and how information technology can bridge the gap | Clinical and Experimental Rheumatology | 2016 | 17 |
| 37 | Outcome Measures in Psoriatic Arthritis | Rheumatic Disease Clinics of North America | 2015 | 15 |
| 38 | Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate | Rheumatology | 2016 | 15 |
| 39 | Recommendations for the Reporting of Harms in Manuscripts on Clinical Trials Assessing Osteoarthritis Drugs: A Consensus Statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) | Drugs and Aging | 2019 | 15 |
| 40 | Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey | Arthritis Research and Therapy | 2019 | 14 |
| 41 | Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus | Rheumatology | 2019 | 14 |
| 42 | Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index | Rheumatology | 2022 | 14 |
| 43 | Quantifying circulating Th17 cells by qPCR: potential as diagnostic biomarker for rheumatoid arthritis | Rheumatology | 2019 | 13 |
| 44 | Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab | Rheumatology | 2022 | 13 |
| 45 | Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment | Arthritis Research and Therapy | 2021 | 11 |
| 46 | The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort | Rheumatology | 2017 | 10 |
| 47 | Phenotypic analysis of pyrin-associated autoinflammation with neutrophilic dermatosis patients during treatment | Rheumatology | 2021 | 10 |
| 48 | The new ACR/EULAR criteria for rheumatoid arthritis can identify patients with same disease activity but less damage by ultrasound | European Journal of Rheumatology | 2017 | 8 |
| 49 | Rescue Analgesic Medication Use by Patients Treated with Triamcinolone Acetonide Extended-Release for Knee Osteoarthritis Pain: Pooled Analysis of Three Phase 2/3 Randomized Clinical Trials | Pain and Therapy | 2019 | 8 |
| 50 | Comment on: British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: reply | Rheumatology | 2020 | 8 |
